



HOUSE OF COMMONS

LONDON SW1A 0AA

The Rt Hon James Murray MP
Secretary of State for Health and Social Care
Department of Health and Social Care
Ministerial Correspondence and Public Enquiries Unit
39 Victoria Street
London
SW1H 0EU

Our Ref: BC70692

9 June 2026

Dear James,

Re: UK-US Pharmaceutical Deal

I am writing in relation to the proposed pharmaceutical deal between the UK and the US.

Many constituents of Southgate and Wood Green have contacted me to share concerns about the lack of transparency surrounding the deal, including its potential implications for NHS spending. Of particular concern is the possibility that rising pharmaceutical costs could place additional pressure on NHS budgets, with consequences for the affordability and accessibility of medicines. At a time when many areas of the NHS are in urgent need of additional investment, constituents believe that the increased expenditure envisaged by this deal warrants further scrutiny to determine whether it is justified and represents the best use of public funds.

I was pleased to see the Government confirm that an impact assessment had been undertaken for this deal, and I believe many of my constituents' concerns could be addressed by permitting the publication of this assessment. Parliament and the public deserve access to a full evaluation of the expected benefits and risks before these changes are fully implemented.

As you know, this deal would increase the spending on new medicines from roughly 0.3% to 0.6% of GDP by 2036. Given this significant rise in expenditure relative to other departments, publication of the impact assessment is essential to ensure transparency and demonstrate that this represents the best possible value for money for working people.

Therefore, I would be grateful if you could share with me any plans the Government have to publish the impact assessment and the reasons why this has been initially refused.

Yours sincerely,

Bambos

Bambos Charalambous MP